"For advanced, compassionate cancer care, patients and their families have trusted St. Luke's Cancer Institute for more than 50 years. Today we're a network of five cancer centers dedicated to state-of-the-art treatment close to home; patient-centered care and support; cutting-edge research; and community prevention, education, and early detection initiatives. During your cancer journey, we'll be with you and your family every step of the way, treating your cancer, easing symptoms and side effects, and strengthening you physically, mentally, and emotionally."

During the past decade, Saint Luke's Cancer Institute - Nampa conducted 150 clinical trials. In the 10-year time frame, 150 clinical trials started and 71 clinical trials were completed, i.e. on average, 47.3% percent of trials that started reached the finish line to date. In the past 5 years, 42 clinical trials started and 50 clinical trials were completed. i.e. 119% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Saint Luke's Cancer Institute - Nampa" #1 sponsor was "National Cancer Institute (NCI)" with 103 trials, followed by "SWOG Cancer Research Network" with 39 trials sponsored, "Alliance for Clinical Trials in Oncology" with 33 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 17 trials sponsored and "NRG Oncology" with 17 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Saint Luke's Cancer Institute - Nampa" #1 collaborator was "National Cancer Institute (NCI)" with 113 trials as a collaborator, "NRG Oncology" with 24 trials as a collaborator, "Canadian Cancer Trials Group" with 11 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 2 trials as a collaborator. Other collaborators include 22 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "Saint Luke's Cancer Institute - Nampa" are "Stage IV Lung Cancer AJCC v8" (11 trials), "Recurrent Ovarian Carcinoma" (9 trials), "Invasive Breast Carcinoma" (8 trials), "Recurrent Lung Non-Small Cell Carcinoma" (8 trials) and "Recurrent Squamous Cell Lung Carcinoma" (8 trials). Many other conditions were trialed in "Saint Luke's Cancer Institute - Nampa" in a lesser frequency.

Most popular intervention types in "Saint Luke's Cancer Institute - Nampa" are "Drug" (173 trials), "Other" (129 trials), "Biological" (95 trials), "Procedure" (66 trials) and "Radiation" (35 trials). Other intervention types were less common.

The name of intervention was led by "Quality-of-Life Assessment" (59 trials), "Laboratory Biomarker Analysis" (56 trials), "Questionnaire Administration" (43 trials), "Computed Tomography" (39 trials) and "Biospecimen Collection" (35 trials). Other intervention names were less common.

The vast majority of trials in "Saint Luke's Cancer Institute - Nampa" are 179 trials for "All" genders, 34 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Saint Luke's Cancer Institute - Nampa". undefined are not yet recruiting, 65 are recruiting, 107 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Saint Luke's Cancer Institute - Nampa, 6 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Saint Luke's Cancer Institute - Nampa, 5 "Phase 1" clinical trials were conducted, 108 "Phase 2" clinical trials and 118 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".